Status:
UNKNOWN
Posterior Capsule Opafication of Different Hydrophobic Acrylic Intraocular Lenses: Vivinex iSert P261 vs.Clareon IOL
Lead Sponsor:
Medical University of Vienna
Conditions:
Age Related Cataracts
Eligibility:
All Genders
40-90 years
Phase:
NA
Brief Summary
On the day of surgery, the first eye to be operated is randomised to receive a Vivinex , HOYA Surgical Optics GmbH or an Clareon, Alcon, Fort Worth, Texas. The second eye to be operated receives the o...
Eligibility Criteria
Inclusion
- Bilateral age-related cataract for which phacoemulsification extraction and posterior IOL implantation has planned
- Age 50 and older
- Visual potential in both eyes of 20/30 or better as determined by investigators estimation
- Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
Exclusion
- Preceding intraocular surgery or ocular trauma
- Relevant other ophthalmic diseases (such as pseudoexfoliation, glaucoma, uveitis, retinal degenerations, etc.)
- Laser treatment
- Uncontrolled systemic or ocular disease
- Infectious disease
- Pregnancy/Nursing
Key Trial Info
Start Date :
January 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04369482
Start Date
January 1 2019
End Date
February 1 2023
Last Update
May 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Vienna Allgemeines Krankenhaus
Vienna, Austria, 1090